High-throughput processes (up to 1,000 Ab/day) with up to 3-step automated purification is perfect for large-scale screening from AI-based designs. WuXian Transient provides high-yield, high-quality protein suitable for animal studies and other critical lead molecule assessment projects. WuXian TM Transient Platform
Popular Packages
Reference Yield
Timeline
QC
96 x 0.8 mL 24 x 3 mL
100-800 μg 0.5-2 mg
2 weeks 2-3 weeks 2-3 weeks
A280, Caliper (R/NR), and SEC-HPLC
20 mL
3-10 mg, average 4.5 mg after 2-step purification
<0.5 EU/mg endotoxin control, QC incl. Titer, A280, Caliper (R/NR) or SDS-PAGE, SEC-HPLC
400-1,000 mg RP-HPLC, bioburden, DSF, DSC, SPR, LC/MS, SEC-MALS, peptide mapping, glycan profiling, cIEF, CHO HCP, residual DNA, ELISA, Western blot, freeze thaw study, micro-developability testing 3 weeks
1 L Additional QC
WuXian TM Express Platform
If you need more than a few grams of protein (e.g., developability studies), stable pool expression via the WuXian Express Platform is ideal. Our stable pool easily produces high-quantity and high-quality protein in 5-6 weeks in a shaker flask, wavebag or bioreactor.
Popular Packages
Reference Yield
Timeline
QC
<0.5 EU/mg endotoxin control, QC incl. Titer, A280, Caliper (R/NR) or SDS-PAGE, SEC-HPLC
20 mL
20 mg
2-3 weeks
1 L - 25 L Additional QC
1 - 25 g RP-HPLC, bioburden, DSF, DSC, SPR, LC/MS, SEC-MALS, peptide mapping, glycan profiling, cIEF, CHO HCP, residual DNA, ELISA, Western blot, freeze thaw study, micro-developability testing 6-7 weeks
Comparable Product Quality of Different Scales
cIEF
GLYCAN
SEC_LC
SDS_CALIPER
100
100
0 20 40 60 80
0 20 40 60 80
50
50
0
0
Main Peak (%) HMW (%)
LMW (%)
200 L 1st-2,000 L 2nd-2,000 L Main Peak (%) Acidic Species (%) Basic Species (%)
200 L 1st-2,000 L 2nd-2,000 L G0 G0F Man5 G1F G2F
NR
R
200 L 1st-2,000 L 2nd-2,000 L
200 L 1st-2,000 L 2nd-2,000 L
Similar product quality is observed among different scales of WuXian Express (one transfection)
Learn more: Protein Sciences: Early-Stage R&D Mammalian Platform
About WuXi Biologics
WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.
The world’s leading global single-source platform from concept to commercialization.
wuxibiologics.com | info@wuxibiologics.com
5-9-2024
Powered by FlippingBook